Haemonetics Corp (HAE)
95.73
+0.93
(+0.98%)
USD |
NYSE |
May 17, 16:00
95.76
+0.02
(+0.03%)
After-Hours: 20:00
Haemonetics Enterprise Value: 5.491B for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 5.491B |
| May 16, 2024 | 5.444B |
| May 15, 2024 | 5.529B |
| May 14, 2024 | 5.574B |
| May 13, 2024 | 5.515B |
| May 10, 2024 | 5.497B |
| May 09, 2024 | 5.332B |
| May 08, 2024 | 5.365B |
| May 07, 2024 | 5.464B |
| May 06, 2024 | 5.473B |
| May 03, 2024 | 5.423B |
| May 02, 2024 | 5.369B |
| May 01, 2024 | 5.308B |
| April 30, 2024 | 5.299B |
| April 29, 2024 | 5.276B |
| April 26, 2024 | 5.250B |
| April 25, 2024 | 5.081B |
| April 24, 2024 | 5.008B |
| April 23, 2024 | 4.949B |
| April 22, 2024 | 4.876B |
| April 19, 2024 | 4.755B |
| April 18, 2024 | 4.868B |
| April 17, 2024 | 4.940B |
| April 16, 2024 | 4.904B |
| April 15, 2024 | 4.940B |
| Date | Value |
|---|---|
| April 12, 2024 | 4.957B |
| April 11, 2024 | 5.023B |
| April 10, 2024 | 5.004B |
| April 09, 2024 | 5.050B |
| April 08, 2024 | 4.962B |
| April 05, 2024 | 4.928B |
| April 04, 2024 | 4.940B |
| April 03, 2024 | 4.891B |
| April 02, 2024 | 4.904B |
| April 01, 2024 | 4.935B |
| March 31, 2024 | 4.964B |
| March 28, 2024 | 5.011B |
| March 27, 2024 | 4.947B |
| March 26, 2024 | 4.823B |
| March 25, 2024 | 4.832B |
| March 22, 2024 | 4.754B |
| March 21, 2024 | 4.754B |
| March 20, 2024 | 4.730B |
| March 19, 2024 | 4.613B |
| March 18, 2024 | 4.526B |
| March 15, 2024 | 4.476B |
| March 14, 2024 | 4.516B |
| March 13, 2024 | 4.554B |
| March 12, 2024 | 4.581B |
| March 11, 2024 | 4.656B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
2.777B
Minimum
Jan 27 2022
7.278B
Maximum
Aug 16 2019
4.877B
Average
4.781B
Median
Enterprise Value Benchmarks
| ResMed Inc | 32.88B |
| Stryker Corp | 137.95B |
| Masimo Corp | 7.314B |
| Insulet Corp | 13.77B |
| InfuSystems Holdings Inc | 166.25M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 20.37M |
| Revenue (Quarterly) | 343.29M |
| Total Expenses (Quarterly) | 145.96M |
| EPS Diluted (Quarterly) | 0.40 |
| Gross Profit Margin (Quarterly) | 51.24% |
| Profit Margin (Quarterly) | 5.93% |
| Earnings Yield | 2.39% |
| Operating Earnings Yield | 3.56% |
| Normalized Earnings Yield | 2.553 |